Arcus Biosciences (RCUS) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcus Biosciences, Inc. is running a Phase 1 trial called “A Phase 1, Open-Label Study to Characterize the Metabolism, Excretion, and Mass Balance of a Single Intravenous Dose of 100 mg Containing 75 µCi of [14C]-Quemliclustat in Healthy Adult Male Participants.” The goal is to map how quemliclustat moves through and leaves the body, which is a key step before larger patient studies and broader investment theses.
The study tests a single intravenous dose of quemliclustat, a small-molecule drug candidate given with a tiny amount of radioactive label. The aim is to track absorption and elimination to understand safety margins and dosing for future oncology or related programs in the Arcus pipeline.
This is an interventional study with one treatment group, where all healthy male participants receive the same dose of [14C]-quemliclustat. The design is open-label, meaning no placebo or blinding, and the main purpose is basic research on drug handling in the body rather than direct clinical benefit.
The trial was first submitted on January 16, 2026, which signals a recent start to human work on this specific metabolism package. The latest update was filed on February 9, 2026, showing that the record is current and that the company is actively maintaining progress disclosures for this program.
For investors, this update supports the view that Arcus is advancing quemliclustat methodically through early-stage development, which can help underpin confidence in the broader RCUS pipeline story. While Phase 1 mass balance data will not move revenue near term, clean results could improve sentiment, differentiate Arcus in competitive immuno-oncology, and slightly de-risk future partnering or combo strategies versus peers.
The study is currently recruiting and remains active, with further operational and scientific details available on the ClinicalTrials.gov portal under the listed identifier.
To learn more about RCUS’s potential, visit the Arcus Biosciences drug pipeline page.